Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib plus gemcitabine versus gemcitabine alone in previously untreated metastatic pancreatic cancer
2012-003547-29Phase 2Terminated
- Sponsor
- Onconova Therapeutics, Inc.
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) comparing rigosertib sodium + gemcitabine with gemcitabine alone (2 arms). Primary endpoint: Overall survival. Started Oct 2012; status: terminated.
02
Drugs
rigosertibgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2012-003547-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003547-29.